WASHINGTON (dpa-AFX) - Revvity, Inc. (RVTY), a life sciences and diagnostics company, on Tuesday revised up its annual guidance.
For fiscal 2026, the company now expects pro forma adjusted earnings of $5.30 to $5.40 per share, compared with the earlier expectation of $5.20 to $5.30 per share. Revvity now anticipates total revenue of $2.83 billion to $2.86 billion, higher than the earlier guidance of $2.81 billion to $2.84 billion.
Prahlad Singh, CEO of Revvity, said: 'As we enter the second half of the year, given the clear momentum in our end markets, we are utilizing a portion of recently received tariff refunds to increase investments across the business, capitalize on emerging opportunities, and support future growth.'
RVTY was down by 0.62% at $114.49 in the pre-market trade on the New York Stock Exchange.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
